Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
NCT07206290 on ClinicalTrials.gov · last registry update 2025-10-03
Registered but not yet open, with 120 participants planned. Due to report 30 November 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Change in first morning void UACR. Sponsors move these dates routinely; any movement since this site started watching is listed below. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- survodutide
- Sponsor
- University Medical Center Groningen
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2026-03-02
- Primary completion
- 2027-11-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in first morning void UACR
Conditions studied
Chronic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.